| Malignant neoplasm of breast
Ibrance vs Verzenio
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Ibrance vs Verzenio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVerzenio has a higher rate of injection site reactions vs Ibrance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Verzenio but not Ibrance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ibrance
Verzenio
At A Glance
Oral
Once daily (21 of 28 days)
CDK4/6 inhibitor
Oral
Twice daily
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Malignant neoplasm of breast
- Carcinoma breast stage IV
Dosing
Malignant neoplasm of breast 125 mg orally once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle; taken with food. Dose may be reduced to 100 mg or 75 mg for adverse reactions; patients with severe hepatic impairment (Child-Pugh C) start at 75 mg once daily.
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeusia
Serious Neutropenia, leukopenia, infections, anemia
Postmarketing Interstitial lung disease (ILD)/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome (PPES)
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Pharmacology
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6; it blocks progression of ER-positive breast cancer cells from G1 into S phase of the cell cycle, and in combination with antiestrogens decreases Rb protein phosphorylation, reduces E2F expression, and increases growth arrest.
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IbranceView full Ibrance profile
VerzenioView full Verzenio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.